Collagenex has confirmed that sansrosa (now called COL-118) is due to move from Phase 1 to Phase 2 some time in 2007. This confirms that COL-118 is still several years away from becoming generally available:
From: Collagenex Pharmaceuticals CEO Speaks About His Company, Jan 8, 2007.
In addition to that, we also have a compound, which is undisclosed at the moment, but referred to as COL-118, that has been targeted for erythema (the redness that is associated with rosacea and acne). That drug will move from Phase I into Phase II during 2007. I think it’s strategically very important for CollaGenex to continue to leverage our platform technologies to give us clearly differentiated products. All three of the products I have referred to are first in class. Oracea is the first systemic treatment labeled for the treatment of rosacea. Incyclinide will be the first significant new chemical entity, if we are successful in getting approval, in the treatment of acne since Accutane. COL-118 will also be a first as there is currently no product specifically and exclusively indicated for the treatment of redness associated with erythema.
Related Articles:
- Sansrosa composition revealed in patent application
- sansrosa patent [via Rosacea Blog]
- sansrosa started as eye drops ?
- Incyclinide (CollaGenex) gets NIH Funding
- Incyclinide phase 2 for acne
- incyclinide targets conditions other than rosacea
- Periostat (doxycycline) goes generic, get ready for Oracea
- Oracea (40mg slow release doxycycline) shows promise
- how do tetracyclines help rosacea ?
- periostat and metrogel better than metrogel alone
- collagenex: rosacea is a chronic inflammatory disease
